Apimeds Pharmaceuticals US, Inc. SEC filings APUS
Apimeds Pharmaceuticals US, Inc. has 130 filings in SEC EDGAR's recent list, going back to Jan 29, 2024. Its latest annual report, Form 10-K, was filed on May 4, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 13, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| NT 10-Q | Notification of late filing | May 15, 2026 | Mar 31, 2026 |
| 425 | Amendment no. 1 to form 8-k | Apr 9, 2026 | — |
| NT 10-K | Notification of late filing | Mar 31, 2026 | Dec 31, 2025 |
| DEFM14C | Information statement | Feb 27, 2026 | — |
| 425 | Amendment no. 2 to form 8-k | Feb 17, 2026 | — |
| PREM14C | Information statement | Jan 16, 2026 | Jan 16, 2026 |
| 425 | Current report | Dec 2, 2025 | — |
| NT 10-Q | Notification of late filing | Aug 14, 2025 | Jun 30, 2025 |
| NT 10-Q | Notification of late filing | May 15, 2025 | Mar 31, 2025 |
| EFFECT | Filing | May 5, 2025 | — |
| CORRESP | Letter to the SEC | May 5, 2025 | — |
| CORRESP | Letter to the SEC | May 5, 2025 | — |
| UPLOAD | Letter from the SEC | May 5, 2025 | — |
| CORRESP | Letter to the SEC | May 1, 2025 | — |
| CORRESP | Letter to the SEC | May 1, 2025 | — |
| UPLOAD | Letter from the SEC | May 1, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 30, 2025 | — |
| NT 10-K | Notification of late filing | Mar 31, 2025 | Dec 31, 2024 |
| CERT | Nyse american certification | Mar 4, 2025 | — |
| 8-A12B | For registration of certain classes | Mar 3, 2025 | — |
| EFFECT | Filing | Feb 11, 2025 | — |
| CORRESP | Letter to the SEC | Feb 10, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 7, 2025 | — |
| CORRESP | Letter to the SEC | Feb 7, 2025 | — |
| CORRESP | Letter to the SEC | Feb 7, 2025 | — |
| CORRESP | Letter to the SEC | Dec 19, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 16, 2024 | — |
| DRS/A | Filing | Aug 5, 2024 | — |
| DRSLTR | Filing | Aug 2, 2024 | — |
| DRS/A | Filing | Jun 17, 2024 | — |
| DRSLTR | Filing | Jun 14, 2024 | — |
| UPLOAD | Letter from the SEC | May 23, 2024 | — |
| DRSLTR | Filing | May 13, 2024 | — |
| DRS/A | Filing | May 13, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 26, 2024 | — |
| DRS | Filing | Jan 29, 2024 | — |
Showing 36 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- APUS (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Matawan, NJ
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1894525
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.